logo

Montréal to host World Congress of Nephrology: $14M in spinoffs for the metropolis Français

Cision Canadaa day ago
MONTRÉAL, /CNW/ - More than 4,500 congress-goers are expected, 12,600 overnight stays and an estimated $14 million in economic spinoffs: the arrival of the World Congress of Nephrology (WCN) in 2028 promises to be a high point—for the local economy as well as for health research in Québec—and illustrates once again the effectiveness of the collaboration between the Palais des congrès de Montréal, Tourisme Montréal and their partners in attracting major international events.
But the impact of this event goes well beyond the numbers. WCN 2028 will offer Québec and Canadian research an international showcase that will foster scientific partnerships, knowledge transfer and the mobilization of the next medical generation. It's also an opportunity to advance awareness of kidney disease, which affects millions of people around the world.
WCN 2028 received financial support from the International Convention Attraction Fund (ICAF). Funded by the Canadian government and run by Destination Canada, the ICAF supports bids by Canadian cities that wish to host major international conventions, with the goal of positioning Canada as a premier destination for hosting business events.
An anticipated return to Montréal since 2021
Initially planned in Montréal in 2021, following a winning bid led by Dr. Tomoko Takano, professor in the Department of Medicine at McGill University, Palais des congrès Ambassador and current president of the Canadian Society of Nephrology, WCN 2021 had to be held virtually due to the pandemic.
The choice of Montréal to host the WCN is no coincidence. The metropolis, and Québec, have made fundamental contributions to the field of nephrology—historically, clinically and in terms of research. Institutions like McGill University, Université de Montréal and the various CIUSSS networks have long been recognized for their excellence in the field.
This choice not only crowns years of concerted efforts between the Canadian Society of Nephrology and the Société québécoise de néphrologie (Québec Society of Nephrology), for both the 2021 and 2028 congresses, but is, above all, a testament to the renewed trust of the International Society of Nephrology in the local and national organizing committee.
Quotes
"WCN 2028 will promote Québec expertise and research, while generating direct and lasting spinoffs for Montréal. Our city is home to a community of researchers who make important breakthroughs in several fields, and nephrology is one of the medical specialties in which Montréal excels. Contributing to the promotion of local scientific knowhow and Québec's societal progress is an essential aspect of the Palais des congrès de Montréal's mission." – Emmanuelle Legault, President and CEO of the Palais des congrès de Montréal
« We are honoured to welcome the international nephrology community back to Montreal for WCN 2028. This congress represents a unique opportunity to highlight Canadian leadership in kidney care, showcase groundbreaking research, and foster global collaboration. Together with our partners at the Société québécoise de néphrologie (SQN), we look forward to hosting an inclusive, impactful, and forward-thinking event that will inspire innovation and strengthen our shared commitment to improving kidney health worldwide. » – Dr. Tomoko Takano, President of the Canadian Society of Nephrology
"Hosting the World Congress of Nephrology in Montréal confirms once again our metropolis's leadership as a destination par excellence for major international scientific events. This type of congress contributes to strengthening Montréal's strategic position as a knowledge and innovation hub. Beyond the major economic benefits, it's also our ability to mobilize talent from here and beyond that resonates globally. We are delighted to have collaborated with the Palais in hosting this event!" – Yves Lalumière, President and CEO of Tourisme Montréal
About the Palais des congrès de Montréal
A creative solutions centre and a showcase for the city's spirit and expertise, the Palais des congrès de Montréal has been promoting and hosting large-scale events since 1983. Generating significant economic, social and intellectual benefits, it encourages innovation and acts as a force for progress for both Montréal and Québec. The Palais is firmly committed to sustainability and takes numerous innovative, concrete steps to make it a central component of its business development. With one of the highest customer satisfaction rates in the world, the Palais actively contributes to the international reputation of Montréal, the top host city for international events in America for eight years in a row. congresmtl.com
About the Canadian Society of Nephrology
The Canadian Society of Nephrology (CSN) is a national organization of physicians, scientists and kidney health professionals devoted to improving the quality of life of people with kidney disease. Driven by a vision of lifelong kidney health, the CSN advances excellence in nephrology through five key pillars:
Establishing and promoting care standards
Advocating equitable access to kidney services
Ensuring continuing education
Championing original research
Developing a thriving professional community
The Society is a trusted voice in the field of kidney care in Canada and internationally, and is committed to supporting innovation, collaboration and leadership in nephrology. For more information, visit www.csnscn.ca.
About Tourisme Montréal
Tourisme Montréal is a 100-year-old private, non-profit organization that works to position Montréal as an international-calibre leisure and business travel destination. To this end, the organization is piloting innovative hospitality strategies with a two-fold objective: ensuring that visitors enjoy a memorable experience and maximizing tourism economic spin-offs in a sustainable way with long-term impacts for the city. Uniting nearly 1,000 businesses and organizations working directly or indirectly in tourism, Tourisme Montréal plays a leading role in the management and development of Montréal's tourism business, and makes recommendations on issues surrounding the city's economic, urban and cultural development. For more information, go to mtl.org.
SOURCE Palais des congrès de Montréal
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Worried about radioactive shrimp? CFIA says no sign they were sold here
Worried about radioactive shrimp? CFIA says no sign they were sold here

Global News

time39 minutes ago

  • Global News

Worried about radioactive shrimp? CFIA says no sign they were sold here

Seafood lovers in the U.S. are being warned about a recall over the risk of potentially radioactive shrimp — and no, it's not a character in a new superhero movie. The U.S. Food and Drug Administration on Tuesday issued a warning about a frozen shrimp brand sold at some Walmart stores in the U.S. due to radioactive contamination in one shipment that was identified before it entered the country. The FDA warning covers multiple lots of shrimp sold by distributors in the U.S. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy However, authorities in Canada told Global News that there were no reports of the affected product being sold in Canada. 'The Canadian Food Inspection Agency (CFIA) is aware of the public advisory published by the United States (U.S.) Food and Drug Administration (FDA) advising the U.S. public to not eat, sell, or serve certain imported shrimp. The CFIA is not aware of any Canadian distribution of these recalled products,' a CFIA spokesperson told Global News in an emailed statement. Story continues below advertisement The U.S. notice pertains to certain frozen shrimp products sold by Indonesian company PT Bahari Makmur Sejati, sold in the U.S. under the label BMS Foods. The affected product was sold at Walmart stores in 13 U.S. states — Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Pennsylvania, Texas and West Virginia. The U.S. FDA discovered high levels of Caesium-137 — a radioactive isotope — in a single shipment of the shrimp that did not enter the U.S. The notice said 'exposure to low-level radiation' from the radioactive containment can cause 'an elevated risk of cancer, resulting from damage to DNA within living cells of the body.'

Ocumetics stock continues to climb after bionic lens implant
Ocumetics stock continues to climb after bionic lens implant

The Market Online

timean hour ago

  • The Market Online

Ocumetics stock continues to climb after bionic lens implant

Shares of Ocumetics Technology (TSXV:OTC) are up by almost 400 per cent following Monday's announcement of a historical milestone: the first-in-human implant of a bionic intraocular lens Ocumetics is a Canadian research and product development company focused on vision-correction solutions Ocumetics stock has added 464.52 per cent year-over-year Shares of Ocumetics Technology (TSXV:OTC) are up by almost 400 per cent following Monday's announcement of a historical milestone: the first-in-human implant of a bionic intraocular lens. This content has been prepared as part of a partnership with Ocumetics Technology Corp., and is intended for informational purposes only. Unlike traditional monofocal or multifocal lenses, the Ocumetics Lens is designed to work with the natural movements of the eye, allowing the user to see clearly close up and at a distance without glasses or contacts following cataract surgery. The successful procedure is an important step in the drive to restore dynamic vision, with initial post-operative results expected in the coming weeks and additional implants planned under the clinical trial program over the coming months. Leadership insights 'This is a moment of immense pride for our team and everyone who has believed in Ocumetics from the beginning,' Dean Burns, Ocumetics Technology's president and chief executive officer, stated in Monday's news release. 'For nearly two decades, we've been focused on a bold vision, one that many thought was out of reach. Our scientists, engineers, clinical advisors and partners have poured their hearts into this innovation. Today we celebrate this success, but we know the work is far from done. There are millions of people waiting for us to get the Ocumetics Lens to market, and we are more driven than ever to bring this solution to the world.' 'The Ocumetics accommodating intraocular lens has the potential to reshape the global standard of care first for cataract, and eventually, presbyopia patients,' Burns added. 'This milestone reinforces Ocumetics' position as a leader in the next generation of ophthalmic innovation. With aging populations around the globe demanding better vision solutions, the potential impact of the Ocumetics Lens is profound.' About Ocumetics Technology Ocumetics is a Canadian research and product development company focused on vision-correction solutions, including an intraocular lens that fits within the eye's natural lens compartment. Ocumetics stock (TSXV:OTC) is up by 75 per cent trading at C$1.75 as of 10:51 am ET. The stock has added 464.52 per cent year-over-year. Join the discussion: Find out what investors are saying about this Canadian healthcare technology stock on the Ocumetics Technology Corp. Bullboard, and make sure to explore the rest of Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.

Canadians won't see price of weight-loss drug Mounjaro rise despite U.K. hike
Canadians won't see price of weight-loss drug Mounjaro rise despite U.K. hike

Global News

time4 hours ago

  • Global News

Canadians won't see price of weight-loss drug Mounjaro rise despite U.K. hike

People using the popular weight-loss drug Mounjaro in the United Kingdom are set to pay a higher price for it, as pharmaceutical giant Eli Lilly said it will raise the U.K. list price by up to 170 per cent. This comes as U.S. President Donald Trump is trying to get drugmakers to raise prices in Europe to allow for price cuts in the United States. However, Canadians are not going to see a price hike, a spokesperson for Eli Lilly Canada told Global News. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy 'Last week's announcement was specific to the UK, not Canada, so there are no pricing updates to share for Canadian patients,' the spokesperson told Global News in an emailed statement. The new U.K. price, which also applies to Lilly's Type 2 diabetes medicine with the same name, is effective from September. The price for a month's supply of the highest dose of the medicine will increase from £122 to £330 (C$227.98 to C$616.67), the company said. Story continues below advertisement The move reflects how the pharmaceutical industry is navigating policy changes in the United States, by far its most lucrative market, where Trump is pushing for lower domestic prices and encouraging price hikes overseas. Last week, Eli Lilly CEO David Ricks told an investor call that parity between U.S. and European drug pricing was desirable in the long run, though he warned that European governments 'are not signing up to pay more for drugs.' — with files from Reuters

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store